Quindós G, Gil-Alonso S, Marcos-Arias C, Sevillano E, Mateo E, Jauregizar N, Eraso E. Therapeutic tools for oral candidiasis: Current and new antifungal drugs. Med Oral Patol Oral Cir Bucal. 2019 Mar 1;24 (2):e172-80.
doi:10.4317/medoral.22978
http://dx.doi.org/doi:10.4317/medoral.22978
_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
References
|
1. Aguirre Urizar JM. Oral Candidiasis. Rev Iberoam Micol.
2002;19:17-21. |
|
|
|
|
|
2. Sánchez-Vargas LO, Ortiz-López NG, Villar M, Moragues MD,
Aguirre JM, Cashat-Cruz M, et al. Point prevalence, microbiology and
antifungal susceptibility patterns of oral Candida isolates colonizing or
infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol.
2005;22:83-92. |
|
|
|
|
|
3. Marcos-Arias C, Vicente JL, Sahand IH, Eguia A, De-Juan A,
Madariaga L, et al. Isolation of Candida dubliniensis in denture stomatitis.
Arch Oral Biol. 2009;54:127-31. |
|
|
|
|
|
4. Manfredi M, Polonelli L, Aguirre-Urizar JM, Carrozzo M, McCullough
MJ. Urban legends series: oral candidosis. Oral Dis. 2013;19:245-61. |
|
|
|
|
|
5. Miranda-Cadena K, Marcos-Arias C, Mateo E, Aguirre JM,
Quindós G, Eraso E. Prevalence and antifungal susceptibility profiles of
Candida glabrata, Candida parapsilosis and their close-related species in
oral candidiasis. Arch Oral Biol. 2018;95:100-7. |
|
|
|
|
|
6. Ceballos A, Quindós G, Ceballos L. The influence of different
risk behaviors in the appearance of oral candidiasis in AIDS patients. Med
Oral. 2000;5:71-80. |
|
|
|
|
|
7. Garcia-Cuesta C, Sarrion-Pérez MG, Bagán JV. Current
treatment of oral candidiasis: A literature review. J Clin Exp Dent.
2014;6:e576-82. |
|
|
|
|
|
8. Lyu X, Zhao C, Yan ZM, Hua H. Efficacy of nystatin for the
treatment of oral candidiasis: a systematic review and meta-analysis. Drug
Des Devel Ther. 2016;10:1161-71. |
|
|
|
|
|
9. Patil S, Rao RS, Majumdar B, Anil S. Clinical appearance of
oral Candida infection and therapeutic strategies. Front Microbiol.
2015;6:1391. |
|
|
|
|
|
10. López-Pintor RM, Hernández G, de Arriba L, de Andrés A. Oral
candidiasis in patients with renal transplants. Med Oral Patol Oral Cir
Bucal. 2013;18:381-7. |
|
|
|
|
|
11. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA,
Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of
candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin
Infect Dis. 2016;62:e1-50. |
|
|
|
|
|
12. De-La-Torre J, Quindós G, Marcos-Arias C, Marichalar-Mendia X,
Gainza ML, Eraso E, et al. Oral Candida colonization in patients with chronic
periodontitis. Is there any relationship? Rev Iberoam Micol. 2018;35:134-9. |
|
|
|
|
|
13. Coronado-Castellote L, Jiménez-Soriano Y. Clinical and
microbiological diagnosis of oral candidiasis. J Clin Exp Dent.
2013;5:e279-86. |
|
|
|
|
|
14. Gotzsche PC, Johansen HK. Nystatin prophylaxis and treatment
in severely immunodepressed patients. Cochrane Database Syst Rev.
2014;9:CD002033. |
|
|
|
|
|
15. Zhang LW, Fu JY, Hua H, Yan ZM. Efficacy and safety of
miconazole for oral candidiasis: a systematic review and meta-analysis. Oral
Dis. 2016;22:185-95. |
|
|
|
|
|
16. Mukherjee PK, Chen H, Patton LL, Evans S, Lee A, Kumwenda J,
et al. Topical gentian violet compared with nystatin oral suspension for the
treatment of oropharyngeal candidiasis in HIV-1-infected participants. AIDS.
2017;31:81-8. |
|
|
|
|
|
17. Scheibler E, Garcia MCR, Medina da Silva R, Figueiredo MA, Salum
FG, Cherubini K. Use of nystatin and chlorhexidine in oral medicine:
Properties, indications and pitfalls with focus on geriatric patients.
Gerodontology. 2017;34:291-8. |
|
|
|
|
|
18. Marcos-Arias C, Eraso E, Madariaga L, Quindós G. In vitro
activities of natural products against oral Candida isolates from denture
wearers. BMC Complement Altern Med. 2011;11:119 |
|
|
|
|
|
19. Malakhov A, Wen J, Zhang BX, Wang H, Geng H, Chen XD, et al.
Rechargeable anticandidal denture material with sustained release in saliva. Oral
Diseases. 2016;22:391-8. |
|
|
|
|
|
20. Reis PC, Roque LV, Baptista M, Rijo P. Innovative
formulation of nystatin particulate systems in toothpaste for candidiasis
treatment. Pharm Dev Technol. 2016;21:282-7. |
|
|
|
|
|
21. Sardi JC, Gullo FP, Freires IA, Pitangui NS, Segalla MP, Fusco-Almeida
AM, et al. Synthesis, antifungal activity of caffeic acid derivative esters,
and their synergism with fluconazole and nystatin against Candida spp. Diagn
Microbiol Infect Dis. 2016;86:387-91. |
|
|
|
|
|
22. Ai R, Wei J, Ma D, Jiang L, Dan H, Zhou Y, et al. A
meta-analysis of randomized trials assessing the effects of probiotic
preparations on oral candidiasis in the elderly. Arch Oral Biol.
2017;83:187-92. |
|
|
|
|
|
23. Pedraza-Sánchez S, Méndez-León JI, Gonzalez Y, Ventura-Ayala
ML, Herrera MT, Lezana-Fernández JL, et al. Oral administration of human
polyvalent IgG by mouthwash as an adjunctive treatment of chronic oral
candidiasis. Front Immunol. 2018;9:2956. |
|
|
|
|
|
24. Schneider J, Mateo E, Marcos-Arias C, Eiró N, Vizoso F,
Pérez-Fernández R, et al. Antifungal activity of the Human Uterine Cervical
Stem Cells Conditioned Medium (hUCESC-CM) against Candida albicans and other
medically relevant species of Candida. Front Microbiol. 2018;9:2818. |
|
|
|
|
|
25. Wiederhold NP. The antifungal arsenal: alternative drugs and
future targets. Int J Antimicrob Agents. 2018;51:333-9. |
|
|
|
|
|
26. Hamill RJ. Amphotericin B formulations: a comparative review
of efficacy and toxicity. Drugs. 2013;73:919-34. |
|
|
|
|
|
27. Gil-Alonso S, Jauregizar N, Cantón E, Eraso E, Quindós G. In
vitro fungicidal activities of anidulafungin, caspofungin, and micafungin
against Candida glabrata, Candida bracarensis, and Candida nivariensis
evaluated by time-kill studies. Antimicrob Agents Chemother. 2015;59:3615-8. |
|
|
|
|
|
28. Castelli MV, Derita MG, López SN. Novel antifungal agents: a
patent review (2013 - present). Expert Opin Ther Pat. 2017;27:415-26. |
|
|
|
|
|
29. Roque L, Alopaeus J, Reis C, Rijo P, Molpeceres J,
Hagesaether E, et al. Mucoadhesive assessment of different antifungal
nanoformulations. Bioinspir Biomim. 2018;13:055001. |
|
|
|
|
|
30. Iqbal Z, Zafar MS. Role of antifungal medicaments added to
tissue conditioners: A systematic review. J Prosthodont Res. 2016;60:231-9. |
|
|
|
|
|
31. Voltan AR, Quindós G, Alarcón KP, Fusco-Almeida AM,
Mendes-Giannini MJ, Chorilli M. Fungal diseases: could nanostructured drug
delivery systems be a novel paradigm for therapy? Int J Nanomedicine.
2016;11:3715-30. |
|
|
|
|
|
32. Vazquez JA, Sobel JD. Miconazole mucoadhesive tablets: a
novel delivery system. Clin Infect Dis. 2012;54:1480-4. |
|
|
|
|
|
33. Hellfritzsch M, Pottegård A, Pedersen AJ, Burghle A,
Mouaanaki F, Hallas J, et al. Topical antimycotics for oral candidiasis in
warfarin users. Basic Clin Pharmacol Toxicol. 2017;120:368-72. |
|
|
|
|
|
34. Oude Lashof AM, De Bock R, Herbrecht R, de Pauw BE, Krcmery
V, Aoun M, et al. An open multicentre comparative study of the efficacy, safety
and tolerance of fluconazole and itraconazole in the treatment of cancer
patients with oropharyngeal candidiasis. Eur J Cancer. 2004;40:1314-9. |
|
|
|
|
|
35. De-la-Torre J, Ortiz-Samperio ME, Marcos-Arias C,
Marichalar-Mendia X, Eraso E, Echebarria-Goicouria MÁ, et al. In vitro
antifungal susceptibility of oral Candida isolates from patients suffering
from caries and chronic periodontitis. Mycopathologia. 2017;182:471-85. |
|
|
|
|
|
36. Carrillo-Mu-oz AJ, Quindós G, Ruesga M, Alonso R, del Valle
O, Hernández-Molina JM, et al. Antifungal activity of posaconazole compared
with fluconazole and amphotericin B against yeasts from oropharyngeal
candidiasis and other infections. J Antimicrob Chemother. 2005;55:317-9. |
|
|
|
|
|
37. Azanza Perea JR, Sádaba Díaz de Rada B. Pharmacological
profile of isavuconazole. Rev Iberoam Micol. 2018;35:186-191. |
|
|
|
|
|
38. Quindós G, Villar-Vidal M, Eraso E. Actividad de la
micafungina contra las biopelículas fúngicas. Rev Iberoam Micol.
2009;26:49-55. |
|
|
|
|
|
39. Gil-Alonso S, Jauregizar N, Eraso E, Quindós G.
Postantifungal effect of caspofungin against the Candida albicans and Candida
parapsilosis clades. Diagn Microbiol Infect Dis. 2016;86:172-7. |
|
|
|
|
|
40. Gil-Alonso S, Jauregizar N, Eraso E, Quindós G.
Postantifungal effect of micafungin against the species complexes of Candida
albicans and Candida parapsilosis. PLoS One. 2015;10:e0132730. |
|